Posts by: Charles Moore

News

Horizon Pharma plc, based in Dublin, Ireland, has announced that it has initiated a Phase 1 clinical study to evaluate Actimmune (interferon gamma-1b) in combination with nivolumab, an immunoglobulin (Ig) G4 monoclonal antibody ... Read more

December 16, 2015December 16, 2015

Novel Bi-Specific Antibody Seen to Target Cancer Cells

News

Immune Pharmaceuticals Inc., a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, announced new data pertaining to a novel bi-specific antibody for cancer treatment in ... Read more

October 30, 2015October 30, 2015

MacroGenics Regains Global Rights to Cancer Drug, Collaborates With Merck

News

Rockville, Maryland-based, clinical-stage biopharmaceutical company MacroGenics, Inc., announced this week that French pharmaceutical company Servier has given notice that it will not exercise its option to regional licensing rights for ... Read more

October 6, 2015October 6, 2015

Bristol-Myers Squibb’s Opdivo (nivolumab) Demonstrates Superior Renal Cell Carcinoma Survival in a Phase 3 Trial Compared to Standard of Care

News

Bristol-Myers Squibb Company announced results from CheckMate -025, a Phase 3 clinical study comparing BMS’s drug Opdivo (nivolumab) to everolimus in advanced renal cell carcinoma (RCC) after prior anti-angiogenic treatment. The ... Read more

September 10, 2015September 10, 2015

OncoSec Advances ‘Smart’ Electroporation Technology For Minimally Invasive Immunotherapy

News

OncoSec Medical Incorporated (OncoSec), a biopharmaceutical company focused on developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse, for treatment of cancer, presented recent progress advances in the field of ... Read more

July 20, 2015July 23, 2015

Merck KGaA, Darmstadt, Germany Collaborates to Accelerate Immuno-Oncology Research

News

This year, Darmstadt, Germany-based Merck KGaA — the oldest pharmaceutical and chemical company in the world, established in 1668 — is celebrating 125 years of business in the U.S. The company ... Read more

July 5, 2015July 9, 2015

Chimeric Antigen Receptor (CAR) T cell Immunotherapy – Competitive Landscape, Technology and Pipeline Analysis, 2015 Released

News

For decades, the main avenues of cancer treatment have been surgery, chemotherapy, and radiation therapy. However, over the past decade, targeted therapies like imatinib (Gleevec) and trastuzumab (Herceptin) — drugs ... Read more

June 16, 2015June 19, 2015

Research and Markets Releases Global Cancer Immunotherapy Market Outlook For 2020

News

Dublin based market analysis firm Research and Markets has announced the addition of the “Global Cancer Immunotherapy Market Outlook 2020” report to their available offerings. The report notes that cancer immunotherapies ... Read more

April 7, 2015April 7, 2015

RXi Pharmaceuticals and MirImmune LLC Ink Exclusive sd-rxRNA Cancer Immunotherapy Technology Licensing Agreement

News

Marlborough, Massachusetts based RXi Pharmaceuticals Corporation and privately-held, Cambridge, MA-headquartered MirImmune LLC, have jointly announced their entering into an exclusive license agreement to develop RXi’s novel and proprietary sd-rxRNA technology ... Read more

March 27, 2015March 27, 2015

Immunomagnetic Assay On-a-Chip Detects And Analyzes Circulating Tumor Cells

News

Dr. John X.J. Zhang, PhD and his team of bioengineers from the Thayer School of Engineering at the private Ivy League research university Dartmouth College in Hanover, New Hampshire have ... Read more